The aldose-reductase inhibitor fidarestat may be an effective treatment for altering the progression of painful diabetic neuropathy.
That is the conclusion of Japanese researchers after they conducted a 52-week, multi-center, placebo-controlled, double-blinded study.
According to the October issue of Diabetes Care, a total of 279 patients with diabetic neuropathy were treated with fidarestat or a placebo at a daily dose of one mg for 52 weeks.
By the end of the study, symptoms such as numbness, spontaneous pain, sensation of rigidity, burning or prickling sensations in the sole upon walking, heaviness in the foot, and partial loss of sensation were improved in the fidarestat group. The placebo group showed no improvement and significant deterioration on one measure.
Aldose-reductase inhibitors—drugs for nerves that have been exposed to high blood glucose levels—work by inhibiting some of the chemical imbalances that occur in the nerves, according to the University Health Network of Ontario, Canada.